A Phase 3 interventional study of adalimumab (D2E7) and placebo in Ankylosing Spondylitis, sponsored by Abbott. Completed at 9 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-28.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing adalimumab in Spondylitis, Ankylosing — 2 open to participants now, 3 under way, none of them phase 3. Adalimumab · Spondylitis, Ankylosing.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, this one is the 9th largest by enrollment, is the only one that started in 2003, is one of 7 in phase 3, and was the 2nd registered.
533 studies on the registry are indexed under Spondylitis, Ankylosing; 98 are open to participants now.
Browse Spondylitis, Ankylosing studies →2 of the 19 studies testing adalimumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
The Affiliated Hospital Of Guizhou Medical University · Sites in China
Ages 18+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 8 · Phase 4 8
First in 2003; this study’s year is marked. 1 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is close to the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.
Median enrollment 80 across the 19 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 19 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 7 studies filed under Spondylitis, Ankylosing — fewer than ten, so there is no comparison to draw.
1 of the studies testing adalimumab in Spondylitis, Ankylosing that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06833112The Affiliated Hospital Of Guizhou Medical UniversityInterleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing adalimumab in Spondylitis, Ankylosing, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to assess the safety and clinical efficacy of adalimumab in subjects with active ankylosing spondylitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Biological: adalimumab (D2E7)
Biological: placebo
Adalimumab 40 mg every other week (eow)
Also known as: ABT-D2E7, adalimumab, Humira
Placebo every other week (eow)
Number of Subjects With a Reduction in Signs and Symptoms as Measured by Assessments of Ankylosing Spondylitis (ASAS) 20 Response at Week 12
ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BAth Ankylosing Spondylitis Functional Index (BASFI) VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.
Time frame: Week 12
Mean Change in the Modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) Compared Against a Historical Control Group (Outcomes in Ankylosing Spondylitis International Study [OASIS]) Using the ANCOVA Model Adjusting for Baseline mSASSS Score
Radiographic progression was based on change in mSASSS scoring (comparison of the means) from double-blind Baseline visit to Week 104. The mSASSS is the sum of the lumbar and cervical spine score ( 0 \[no change\] to 72 \[progression\]), derived from scoring the anterior site of the lumbar spine (T12 to S1) and the cervical spine (C2 to T1) as either 0 (normal), 1 (erosion, sclerosis, or squaring), 2 (syndesmophyte), 3 (bridging syndesmophyte), or N (vertebral body not evaluable). Data from NCT00195819 was compared with data from AS patients in OASIS.
Time frame: Baseline and Week 104
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) 20 - Through Week 260 of Adalimumab Exposure
ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BASFI VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured by Assessments in Ankylosing Spondylitis (ASAS) ASAS 50 Through Week 260 of Adalimumab Exposure
ASAS 50 responders - improvement of \>=50% and absolute improvement of \>=20 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity; (0\[none\]-100\[severe\]) VAS scale; Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not overall global scale.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Assessments of Ankylosing Spondylitis (ASAS) ASAS 70 Through Week 260 of Adalimumab Exposure
ASAS 70 responders - improvement of \>=70% and absolute improvement of \>=30 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100\[severe\]) Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; 1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Patient's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260
Evaluation of the effect of adalimumab 40 mg every other week (eow) on patient's global assessment of disease activity. The patient was to assess his/her disease activity in the past week using a visual analog scale (VAS) on a scale of 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.
Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Patient's Global Assessment of Disease Activity (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
The patient assesses his/her disease activity for the past week using a Patient Global Assessment of Disease on visual analog scale (VAS) with 0 being none and 100 being severe.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in the Bath Ankylosing Spondylitis Functional Index (BASFI) in Subjects With Adalimumab Exposure Through Week 260
BASFI consist of a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The BASFI score was derived based on the average of questions 1 through 10. The first 8 questions considered activities related to functional anatomy and the final 2 questions assessed the subject's ability to cope with everyday life over the last week. A 10 cm visual analog scale (VAS) was used to answer the questions and the mean of the ten scales gave the BASFI score a value between 0 (easy) and 10 (impossible).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, 244, and 260
BASFI (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
BASFI consisted of 10 Visual Analog Scale (VAS) questions with a response ranging from 0 (easy) to 100 (impossible). The BASFI score was derived based on the average of questions 1 through 10. A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Total Back Pain Visual Analog Scale (VAS) in Subjects With Adalimumab Exposure Through Week 260
Evaluation of the effect of 40 mg every other week (eow) adalimumab on Total Back Pain VAS. The subject was to assess his/her disease activity in the past week using a total spine VAS on a scale 0 (no pain) to 100 (severe pain).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Total Back Pain (an Individual Component of ASAS 20) Through Week 260 of Adalimumab Exposure
A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.
Time frame: Weeks 12, 24, 52, 76, 128, 152, 180, 208, 220, 232, 244, and 260
Mean Change in Inflammation (Mean of BASDAI Questions 5 and 6) in Subjects With Adalimumab Exposure Through Week 260
The inflammation score is the mean of the two morning stiffness-related BASDAI visual analog scale (VAS) scores (items 5 and 6 of the BASDAI) of 0 (none) to 10 (very severe). A decrease in inflammation represents improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Inflammation (Individual Component of ASAS 20) (Mean of BASDAI Questions 5 and 6) Through Week 260 of Adalimumab Exposure
A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline in inflammation (mean of the BASDAI questions 5 and 6 on scale of 0 \[none\] to 10 \[very severe\].
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 20 Through Week 260 of Adalimumab Exposure
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100(very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (very severe). Improvement in BASDAI by 20% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 Through Week 260 of Adalimumab Exposure
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 50% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Reduction of Signs and Symptoms as Measured in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 70 Through Week 260 of Adalimumab Exposure
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 70% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in BASDAI in Subjects With Adalimumab Exposure Through Week 260
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (severe). A decrease in BASDAI represents improvement. BASDAI Scoring: 1) Measure each item of the BASDAI in centimeters (out of a total of 10) 2) BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in C-Reactive Protein (CRP) (mg/dL) in Subjects With Adalimumab Exposure Through Week 260
Evaluation of the mean changes in CRP in subjects with adalimumab exposure from Baseline through 5 years. The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation via the use of an ultrasensitive assay. A decrease in the level of CRP indicate reduction in inflammation. A decrease in CRP indicates improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis (ASAS) 40 - Through Week 260 of Adalimumab Exposure
ASAS 40 responder: improvement of \>= 40% and absolute improvement of \>= 20 units (on a scale of 0 to 100) in \>= 3 of the 4 domains: Patient global assessment (VAS score \[0-100 scale\]); Pain (Total Back Pain VAS score 0-100 scale); Function (BASFI score 0-100 scale); Inflammation (the mean of the two morning stiffness-related BASDAI VAS scores (i.e. the average of items 5 and 6 of the BASDAI. Applied to each scale. In addition, absence of deterioration in the potential remaining domain, where deterioration is defined as a net worsening of \> 0 units (on a scale of 0 to 100).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244 and 260
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Assessments of Ankylosing Spondylitis Ankylosing Spondylitis (ASAS) 5/6 in Subjects With Adalimumab Exposure Through Week 260
The change in ASAS 5/6 was evaluated for the effect of adalimumab on structural damage. ASAS 5/6 criteria is the 20% improvement in 5 out of 6 domains (physical function \[BASFI\], Total Back Pain, Patient's Global Assessment of Disease Activity, Inflammation \[mean of Questions 5 and 6 of the BASDAI\], spinal mobility \[BASMI\], and acute phase reactants \[CRP\]).
Time frame: Weeks 12, 16, 20, 24, 30, 36, 42, 48, 52, 64, 76, 88, 104, 116, 128, 140, 156, 168, 180, 192, 208, 220, 232, 244, and 260
Number of Subjects With a Disease Controlling Clinical Response From Adalimumab as Measured in Partial Remission Response in Subjects With Adalimumab Exposure Through Week 260
Evaluation of the mean changes in BASDAI in subjects with adalimumab exposure from Baseline through 5 years for the effect of adalimumab on structural damage. Partial remission was calculated as follows: A value below 20 on a 0 - 100-point scale in each of the four domains of the ASAS (Patient's Global Assessment of Disease Activity, Pain, Function and Inflammation). Partial remission is also regarded as a low disease activity state.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in the Bath Ankylosing Spondylitis Metrology Index (BASMI) in Subjects With Adalimumab Exposure Through Week 260
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. BASMI 0 = indicates mild disease involvement, 1 = moderate disease, and 2 = severe disease involvement. The results for cervical rotation and lumbar side flexion are the means of the left and right measurements. Scoring range 0-10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Edmonton Ankylosing Spondylitis Metrology Index (EDASMI) in Subjects With Adalimumab Exposure Through Week 260
The EDASMI is a composite spinal mobility index comprised of 4 measures: 1) cervical rotation, 2) lumbar side flexion, 3) chest expansion, and 4) hip internal rotation spread. A grade of 0-4 scoring system was developed for each of the measures. The sum of 4 items (range 0 to 16) provide the EDASMI score. Decrease in EDASMI represents improvement. All EDASMI measures were done with a simple tape measure and recorded in centimeters (cm) by a rheumatologist and a clinician nurse.
Time frame: Weeks 12, 24, 52, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Chest Expansion (CE) in Subjects With Adalimumab Exposure Through Week 260
The patient is in a sitting position on the examination table with the hands on the hips. A pen mark is made at the xiphisternum and a tape measure placed around the circumference of the patient's chest at this level. The patient is asked to take a deep breath and to exhale as completely as possible while looking directly ahead. The measurement (in cm) is noted. The patient is asked to inhale as deeply as possible and the measurement (in cm) is noted. The difference in the 2 measurement points (in cm) constitutes the value for CE. An increase in chest expansion represents improvement
Time frame: Weeks 12, 24, 52,104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) in Subjects With Adalimumab Exposure Through Week 260
MASES is measured by scoring of entheses of 0 (no tenderness) to 3 (severe tenderness) at 13 sites on the body. The score was derived as the sum of the 13 scores divided by 3 and the total range is 0 (no tenderness) to 13 (severe tenderness).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change in the Bath Ankylosing Spondylitis Global Index (BAS-G) in Subjects With Adalimumab Exposure Through Week 260
BAS-G consisted of two questions that asked the subject to indicate, on a 10 cm VAS, the effect the disease had on their well being over 1) last week, and 2) last 6 months. BAS-G was measured by two VAS scores (0 to 100 mm) to reflect the effect of Ankylosing Spondylitis on subject's well-being over the past week and over the last 6 months, respectively. The average of these two scores was reported. The mean of the two scores give a BAS-G score of 0-10.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Swollen Joint Count for 44 Joints (44 SJC) in Subjects With Adalimumab Exposure Through Week 260
Change from Baseline in the swollen joint index. An assessment of 44 joints for SJC done by physical examination. Joint swelling was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).
Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change From Baseline in the Tender Joint Count for 46 Joints (TJC 46) in Subjects With Adalimumab Exposure Through Week 260 of Adalimumab Exposure
Assessment of 46 joints for TJC was done by physical examination. Joint tenderness was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).
Time frame: Weeks 12, 24, 36, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change in Physician's Global Assessment of Disease Activity in Subjects With Adalimumab Exposure Through Week 260
The physician will globally assess the subject's current disease state using a VAS scale with 0 being very good and 100 being very bad.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Nocturnal Pain in Subjects With Adalimumab Exposure Through Week 260
The subject was to assess his/her nocturnal pain intensity for the past week using a Nocturnal Pain Visual Analog Scale (Nocturnal Pain VAS). The range was 0 to 100 mm with no pain being indicated by 0 and worse possible pain by 100.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale in Subjects With Adalimumab Exposure Through Week 260
The FACIT-Fatigue scale: overall score of 13 general questions divided into four primary Quality of Life (QoL) domains: 1) Physical Well-Being, 2) Social/Family Well-Being, 3) Emotional Well-Being, and 4) Functional Well-Being. For each question subject rates his/her condition for the past week on a 5-point scale ranging from 0 (not at all) to 4 (very much). The score ranges from 0 (highest level of fatigue) to 52 with 52 being the lowest level of fatigue.
Time frame: Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change in the SF-36 Health Survey Index Physical Component Summary [PCS] Through Week 260 of Adalimumab Exposure
Change from Baseline in the SF-36 Health Survey Index completed by Subject to help subject keep track of how he/she was feeling and how well he/she was able to do usual activities. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicate improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Number of Subjects With SF-36 Physical Component Summary (PCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0(no functioning)to 100 (highest level of functioning). Responders were subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change in the SF-36 Health Survey Index Mental Component Summary [MCS] Through Week 260 of Adalimumab Exposure
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Change from Baseline in the SF-36 Health Survey Index was completed by Subject. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicated improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Number of Subjects With SF-36 Mental Component Summary (MCS) of Minimal Clinically Important Difference (MCID) Response Through Week 260 of Adalimumab Exposure
SF-36 is a standardized survey completed by Subject, evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Responders are subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change in Health Utilities Index-3 (HUI-3) Through Week 260 of Adalimumab Exposure
Change from baseline in Health Utility Index Mark 3 (HUI-3) was reported. The HUI-3 is a generic approach to the measurement of health status and assessment of HRQL. The HUI-3 was comprised of two complementary components. The first component was a multi-attribute health status classification system that was used to describe health status. The second component was a multi-attribute utility function that was used to value health status as measured within the corresponding multi-attribute health status classification system. An increase in the HUI-3 score represents improvement.
Time frame: Weeks 24, 52, 104, 128, 156, 180, 208, 232, and 260
Mean Change in the Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) in Subjects Through Week 260 of Adalimumab Exposure
ASQoL determined subject's quality of life and is comprised of 18 questions (yes or no) to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score or index. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement.
Time frame: Baseline and at Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Number of Subjects With Ankylosing Spondylitis Quality of Life Questionaire (ASQoL) MCID Response (MCID <= -1.8 Points) Through Week 260 of Adalimumab Exposure
ASQoL determined subject's quality of life comprised of 18 questions to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement. Responders are subjects with MCID \<= -1.8 points. MCID was determined by a \>= 1.8 score decrease during exposure to adalimumab.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Number of Subjects Achieving the Patient Acceptable Symptoms State Through Week 260 of Adalimumab Exposure
Completed by subject at each visit. The MCIS was a patient reported outcome where the subjects were expected to respond (yes/no) to the following question: Considering all the different ways your disease is affecting you, if you would stay in this state for the next months, do you consider that your current state is satisfactory? An increase in PASS indicates improvement. During earlier weeks of the study PASS was measured/reported as minimal clinically important state (MCIS).
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 232, and 260
Mean Change From Baseline in Serum Matrix Metalloproteinase-3 (MMP-3) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
Cartilage and bone degradation were assessed by evaluating changes in MMP-3. A decrease in MMP-3 represents improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change From Baseline in Urine Type II Collagen C Telopeptide (CTX-II) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
Cartilage and bone degradation were assessed by evaluating changes in CTX-II. A decrease in CTX-II represents improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change From Baseline in Serum Type I Collagen N-telopeptide (NTx) in Subjects Treated With Any Dose of Adalimumab Through Week 260 of Adalimumab Exposure
Cartilage degradation and bone resorption were assessed by evaluating changes in NTx. A decrease in NTx represents improvement.
Time frame: Weeks 12, 24, 52, 76, 104, 128, 156, 180, 208, 220, 232, 244, and 260
Mean Change in Spinal Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure
The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.
Time frame: Week 12 and Week 52
Mean Change in Sacroiliac (SI) Spondyloarthritis Research Consortium of Canada (S.P.A.R.C.C.) Magnetic Resonance Imaging (MRI) Index of Disease Activity Score at Weeks 12 and 52 of Adalimumab Exposure
The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.
Time frame: Weeks 12 and 52
The placebo group included subjects who were randomized to placebo even if they received early escape open label adalimumab. The adalimumab exposure group included subjects who were randomized to blinded adalimumab.
| Milestone | Placebo 40 mg Every Other Week (Eow), Subcutaneous (SC) | Any Adalimumab |
|---|---|---|
| Started | 44 | 38 |
| Completed | 42 | 38 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Moved | 1 | 0 |
| Milestone | Placebo 40 mg Every Other Week (Eow), Subcutaneous (SC) | Any Adalimumab |
|---|---|---|
| Started | 0 | 82 |
| Completed | 0 | 62 |
| Not completed | 0 | 20 |
| Withdrew: Adverse event | 0 | 9 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Moved | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 5 |
ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BAth Ankylosing Spondylitis Functional Index (BASFI) VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.
| participants | Adalimumab | Placebo |
|---|---|---|
| Responder | 18 | 12 |
| Non-responder | 20 | 32 |
| Missing | 0 | 0 |
ASAS 20 responders - improvement of \>=20% and absolute improvement of \>=10 units from Baseline in a visual analog scale (VAS) 0 \[no disease activity\]-100 \[high disease activity\]) for \>=3 of 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100 \[severe\]), Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]), BASFI VAS (0 \[easy \]-100\[impossible\]); and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]) and absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 48 |
| Week 24 Responders (n=80) | 52 |
| Week 52 Responders (n=78) | 60 |
| Week 76 Responders (n=75) | 57 |
| Week 104 Responders (n=74) | 60 |
| Week 128 Responders (n=70) | 57 |
| Week 156 Responders (n=69) | 53 |
| Week 180 Responders (n=62) | 47 |
| Week 208 Responders (n=67) | 53 |
| Week 220 Responders (n=64) | 55 |
| Week 232 Responders (n=62) | 50 |
| Week 244 Responders (n=54) | 49 |
| Week 260 Responders (n=27) | 24 |
ASAS 50 responders - improvement of \>=50% and absolute improvement of \>=20 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity; (0\[none\]-100\[severe\]) VAS scale; Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; (1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not overall global scale.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 29 |
| Week 24 Responders (n=80) | 38 |
| Week 52 Responders (n=78) | 45 |
| Week 76 Responders (n=75) | 46 |
| Week 104 Responders (n=74) | 47 |
| Week 128 Responders (n=70) | 46 |
| Week 156 Responders (n=69) | 42 |
| Week 180 Responders (n=62) | 38 |
| Week 208 Responders (n=67) | 37 |
| Week 220 Responders (n=64) | 42 |
| Week 232 Responders (n=62) | 42 |
| Week 244 Responders (n=54) | 40 |
| Week 260 Responders (n=27) | 24 |
ASAS 70 responders - improvement of \>=70% and absolute improvement of \>=30 units (0-100) from Baseline in visual analog scale (VAS) for \>=3 of the 4 domains; Patient's Global Assessment of disease activity VAS; (0\[none\]-100\[severe\]) Total Back Pain VAS; (0 \[no pain\]-100 \[severe\]); BASFI VAS; (0 \[easy \]-100\[impossible\]) and Inflammation VAS; 1 \[no pain\] to 10 \[severe pain\]). In addition, absence of deterioration in the potential remaining domain. Applied to each scale and not to an overall global scale.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 18 |
| Week 24 Responders (n=80) | 27 |
| Week 52 Responders (n=78) | 32 |
| Week 76 Responders (n=75) | 34 |
| Week 104 Responders (n=74) | 35 |
| Week 128 Responders (n=70) | 32 |
| Week 156 Responders (n=69) | 31 |
| Week 180 Responders (n=62) | 24 |
| Week 208 Responders (n=67) | 28 |
| Week 220 Responders (n=64) | 26 |
| Week 232 Responders (n=62) | 28 |
| Week 244 Responders (n=54) | 29 |
| Week 260 Responders (n=27) | 14 |
Evaluation of the effect of adalimumab 40 mg every other week (eow) on patient's global assessment of disease activity. The patient was to assess his/her disease activity in the past week using a visual analog scale (VAS) on a scale of 0 to 100 mm with no activity being indicated by 0 and severe activity by 100.
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -28.55 ± 26.808 |
| Week 24 (n=80) | -32.43 ± 29.047 |
| Week 52 (n=78) | -38.67 ± 26.255 |
| Week 76 (n=75) | -40.85 ± 25.934 |
| Week 104 (n=74) | -42.72 ± 24.263 |
| Week 128 (n=70) | -40.99 ± 27.741 |
| Week 156 (n=69) | -40.86 ± 27.203 |
| Week 180 (n=62) | -41.74 ± 26.622 |
| Week 208 (n=67) | -40.79 ± 26.049 |
| Week 220 (n=64) | -43.41 ± 23.854 |
| Week 232 (n=62) | -42.77 ± 29.574 |
| Week 244 (n=54) | -51.02 ± 23.297 |
| Week 260 (n=27) | -51.26 ± 18.451 |
The patient assesses his/her disease activity for the past week using a Patient Global Assessment of Disease on visual analog scale (VAS) with 0 being none and 100 being severe.
| participants | Adalimumab |
|---|---|
| Week 12 Responder (n=82) | 53 |
| Week 24 Responder (n=80) | 56 |
| Week 52 Responder (n=78) | 61 |
| Week 76 Responder (n=75) | 59 |
| Week 104 Responder (n=74) | 64 |
| Week 128 Responder (n=70) | 57 |
| Week 156 Responder (n=69) | 57 |
| Week 180 Responder (n=62) | 52 |
| Week 208 Responder (n=67) | 56 |
| Week 220 Responder (n=64) | 57 |
| Week 232 Responder (n=62) | 53 |
| Week 244 Responder (n=54) | 50 |
| Week 260 Responder (n=27) | 26 |
BASFI consist of a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The BASFI score was derived based on the average of questions 1 through 10. The first 8 questions considered activities related to functional anatomy and the final 2 questions assessed the subject's ability to cope with everyday life over the last week. A 10 cm visual analog scale (VAS) was used to answer the questions and the mean of the ten scales gave the BASFI score a value between 0 (easy) and 10 (impossible).
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -19.83 ± 23.481 |
| Week 24 (n=80) | -24.39 ± 23.559 |
| Week 52 (n=78) | -27.83 ± 25.325 |
| Week 76 (n=75) | -30.42 ± 24.607 |
| Week 104 (n=74) | -30.51 ± 23.382 |
| Week 128 (n=70) | -30.67 ± 24.209 |
| Week 156 (n=69) | -30.12 ± 24.437 |
| Week 180 (n=62) | -28.76 ± 24.060 |
| Week 208 (n=67) | -29.81 ± 23.976 |
| Week 220 (n=64) | -30.47 ± 23.333 |
| Week 232 (n=62) | -31.35 ± 22.964 |
| Week 244 (n=54) | -36.65 ± 21.847 |
| Week 260 (n=27) | -30.83 ± 22.174 |
BASFI consisted of 10 Visual Analog Scale (VAS) questions with a response ranging from 0 (easy) to 100 (impossible). The BASFI score was derived based on the average of questions 1 through 10. A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.
| participants | Adalimumab |
|---|---|
| Week 12 Responder (n=82) | 46 |
| Week 24 Responder (n=80) | 52 |
| Week 52 Responder (n=78) | 53 |
| Week 76 Responder (n-75) | 55 |
| Week 104 Responder (n=74) | 55 |
| Week 128 Responder (n=70) | 51 |
| Week 156 Responder (n=69) | 50 |
| Week 180 Responder (n=62) | 45 |
| Week 208 Responder (n=67) | 51 |
| Week 220 Responder (n=64) | 47 |
| Week 232 Responder (n=62) | 48 |
| Week 244 Responder (n=54) | 46 |
| Week 260 Responder (n=27) | 22 |
Evaluation of the effect of 40 mg every other week (eow) adalimumab on Total Back Pain VAS. The subject was to assess his/her disease activity in the past week using a total spine VAS on a scale 0 (no pain) to 100 (severe pain).
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -29.30 ± 26.783 |
| Week 24 (n=80) | -31.89 ± 29.675 |
| Week 52 (n=78) | -39.46 ± 26.658 |
| Week 76 (n=75) | -40.89 ± 26.375 |
| Week 104 (n=74) | -43.85 ± 24.730 |
| Week 128 (n=70) | -44.07 ± 25.944 |
| Week 156 (n=69) | -42.67 ± 27.257 |
| Week 180 (n=62) | -41.06 ± 28.604 |
| Week 208 (n=67) | -42.16 ± 27.092 |
| Week 220 (n=64) | -43.77 ± 25.228 |
| Week 232 (n=62) | -42.56 ± 27.844 |
| Week 244 (n=54) | -50.30 ± 23.936 |
| Week 260 (n=27) | -49.41 ± 27.025 |
A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline.
| participants | Adalimumab |
|---|---|
| Week 12 Responder (n=82) | 56 |
| Week 24 Responder (n=80) | 57 |
| Week 52 Responder (n=78) | 66 |
| Week 76 Responder (n=75) | 62 |
| Week 104 Responder (n=74) | 64 |
| Week 128 Responder (n=70) | 62 |
| Week 156 Responder (n=69) | 59 |
| Week 180 Responder (n=62) | 50 |
| Week 208 Responder (n=67) | 56 |
| Week 220 Responder (n=64) | 59 |
| Week 232 Responder (n=62) | 52 |
| Week 244 Responder (n=54) | 53 |
| Week 260 Responder (n=27) | 25 |
The inflammation score is the mean of the two morning stiffness-related BASDAI visual analog scale (VAS) scores (items 5 and 6 of the BASDAI) of 0 (none) to 10 (very severe). A decrease in inflammation represents improvement.
| cm | Adalimumab |
|---|---|
| Week 12 (n=82) | -2.79 ± 2.650 |
| Week 24 (n=80) | -3.29 ± 2.882 |
| Week 52 (n=78) | -3.89 ± 2.663 |
| Week 76 (n=75) | -4.12 ± 2.480 |
| Week 104 (n=74) | -4.50 ± 2.465 |
| Week 128 (n=70) | -4.32 ± 2.512 |
| Week 156 (n=69) | -4.25 ± 2.690 |
| Week 180 (n=62) | -4.21 ± 2.522 |
| Week 208 (n=67) | -4.22 ± 2.553 |
| Week 220 (n=64) | -4.48 ± 2.442 |
| Week 232 (n=62) | -4.51 ± 2.786 |
| Week 244 (n=54) | -4.96 ± 2.357 |
| Week 260 (n=27) | -5.21 ± 2.375 |
A responder is a subject who demonstrates an absolute improvement of at least 10 units and a percentage improvement of at least 20% from Baseline in inflammation (mean of the BASDAI questions 5 and 6 on scale of 0 \[none\] to 10 \[very severe\].
| particpants | Adalimumab |
|---|---|
| Week 12 Responder (n=82) | 52 |
| Week 24 Responder (n=80) | 59 |
| Week 52 Responder (n=78) | 66 |
| Week 76 Responder (n=75) | 64 |
| Week 104 Responder (n=74) | 65 |
| Week 128 Responder (n=70) | 61 |
| Week 156 Responder (n=69) | 55 |
| Week 180 Responder (n=62) | 53 |
| Week 208 Responder (n=67) | 58 |
| Week 220 Responder (n=64) | 57 |
| Week 232 Responder (n=62) | 53 |
| Week 244 Responder (n=54) | 49 |
| Week 260 Responder (n=27) | 25 |
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100(very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (very severe). Improvement in BASDAI by 20% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
| Participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 61 |
| Week 24 Responders (n=80) | 61 |
| Week 52 Responders (n=78) | 64 |
| Week 76 Responders (n=75) | 64 |
| Week 104 Responders (n=74) | 65 |
| Week 128 Responders (n=70) | 60 |
| Week 156 Responders (n=69) | 59 |
| Week 180 Responders (n=62) | 55 |
| Week 208 Responders (n=67) | 61 |
| Week 220 Responders (n=64) | 58 |
| Week 232 Responders (n=62) | 57 |
| Week 244 Responders (n=54) | 51 |
| Week 260 Responders (n=27) | 26 |
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 50% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 32 |
| Week 24 Responders (n=80) | 41 |
| Week 52 Responders (n=78) | 48 |
| Week 76 Responders (n=75) | 52 |
| Week 104 Responders (n=74) | 52 |
| Week 128 Responders (n=70) | 45 |
| Week 156 Responders (n=69) | 51 |
| Week 180 Responders (n=62) | 43 |
| Week 208 Responders (n=67) | 46 |
| Week 220 Responders (n=64) | 48 |
| Week 232 Responders (n=62) | 47 |
| Week 244 Responders (n=54) | 42 |
| Week 260 Responders (n=27) | 25 |
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 to 10. Improvement in BASDAI by 70% was assessed. BASDAI Scoring: 1. Measure each item of the BASDAI in centimeters (out of a total of 10) 2. BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 24 |
| Week 24 Responders (n=80) | 32 |
| Week 52 Responders (n=78) | 34 |
| Week 76 Responders (n=75) | 37 |
| Week 104 Responders (n=74) | 35 |
| Week 128 Responders (n=70) | 37 |
| Week 156 Responders (n=69) | 34 |
| Week 180 Responders (n=62) | 28 |
| Week 208 Responders (n=67) | 35 |
| Week 220 Responders (n=64) | 31 |
| Week 232 Responders (n=62) | 35 |
| Week 244 Responders (n=54) | 30 |
| Week 260 Responders (n=27) | 14 |
The BASDAI is a questionnaire with 6 questions that subject completes by marking answers on a 10-cm Visual Analog Scale (VAS) during the last week with responses that range from 0 (none) to 100 (very severe) and measures severity of fatigue, spinal and peripheral joint pain, localized tenderness and morning stiffness. The final BASDAI score ranges from 0 (none) to 10 (severe). A decrease in BASDAI represents improvement. BASDAI Scoring: 1) Measure each item of the BASDAI in centimeters (out of a total of 10) 2) BASDAI Score = 0.2 (Item 1 + Item 2 + Item 3 + Item 4 + Item 5/2 + Item 6/2).
| cm | Adalimumab |
|---|---|
| Week 12 (n=82) | -2.48 ± 2.305 |
| Week 24 (n=80) | -2.96 ± 2.694 |
| Week 52 (n=78) | -3.41 ± 2.511 |
| Week 76 (n=75) | -3.70 ± 2.486 |
| Week 104 (n=74) | -3.83 ± 2.392 |
| Week 128 (n=70) | -3.64 ± 2.536 |
| Week 156 (n=69) | -3.63 ± 2.583 |
| Week 180 (n=62) | -3.60 ± 2.338 |
| Week 208 (n=67) | -3.70 ± 2.367 |
| Week 220 (n=64) | -3.83 ± 2.384 |
| Week 232 (n=62) | -3.80 ± 2.538 |
| Week 244 (n=54) | -4.36 ± 2.214 |
| Week 260 (n=27) | -4.48 ± 2.011 |
Evaluation of the mean changes in CRP in subjects with adalimumab exposure from Baseline through 5 years. The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation via the use of an ultrasensitive assay. A decrease in the level of CRP indicate reduction in inflammation. A decrease in CRP indicates improvement.
| mg/dL | Adalimumab |
|---|---|
| Week 12 (n=82) | -1.81 ± 2.782 |
| Week 24 (n=80) | -1.81 ± 2.824 |
| Week 52 (n=78) | -1.60 ± 3.581 |
| Week 76 (n=75) | -1.86 ± 2.897 |
| Week 104 (n=74) | -1.90 ± 2.850 |
| Week 128 (n=70) | -1.92 ± 3.028 |
| Week 156 (n=69) | -1.83 ± 3.060 |
| Week 180 (n=62) | -1.99 ± 2.995 |
| Week 208 (n=67) | -1.89 ± 3.063 |
| Week 220 (n=64) | -2.00 ± 3.117 |
| Week 232 (n=62) | -1.67 ± 3.267 |
| Week 244 (n=54) | -2.07 ± 3.252 |
| Week 260 (n=27) | -1.27 ± 1.513 |
ASAS 40 responder: improvement of \>= 40% and absolute improvement of \>= 20 units (on a scale of 0 to 100) in \>= 3 of the 4 domains: Patient global assessment (VAS score \[0-100 scale\]); Pain (Total Back Pain VAS score 0-100 scale); Function (BASFI score 0-100 scale); Inflammation (the mean of the two morning stiffness-related BASDAI VAS scores (i.e. the average of items 5 and 6 of the BASDAI. Applied to each scale. In addition, absence of deterioration in the potential remaining domain, where deterioration is defined as a net worsening of \> 0 units (on a scale of 0 to 100).
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 34 |
| Week 24 Responders (n=80) | 41 |
| Week 52 Responders (n=78) | 48 |
| Week 76 Responders (n=75) | 50 |
| Week 104 Responders (n=74) | 52 |
| Week 128 Responders (n=70) | 47 |
| Week 156 Responders (n=69) | 45 |
| Week 180 Responders (n=62) | 40 |
| Week 208 Responders (n=67) | 44 |
| Week 220 Responders (n=64) | 48 |
| Week 232 Responders (n=62) | 45 |
| Week 244 Responders (n=54) | 42 |
| Week 260 Responders (n=27) | 22 |
The change in ASAS 5/6 was evaluated for the effect of adalimumab on structural damage. ASAS 5/6 criteria is the 20% improvement in 5 out of 6 domains (physical function \[BASFI\], Total Back Pain, Patient's Global Assessment of Disease Activity, Inflammation \[mean of Questions 5 and 6 of the BASDAI\], spinal mobility \[BASMI\], and acute phase reactants \[CRP\]).
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 45 |
| Week 24 Responders (n=80) | 49 |
| Week 52 Responders (n=78) | 55 |
| Week 76 Responders (n=75) | 57 |
| Week 104 Responders (n=74) | 56 |
| Week 128 Responders (n=70) | 53 |
| Week 156 Responders (n=69) | 51 |
| Week 180 Responders (n=62) | 45 |
| Week 208 Responders (n=67) | 48 |
| Week 220 Responders (n=64) | 47 |
| Week 232 Responders (n=62) | 49 |
| Week 244 Responders (n=54) | 42 |
| Week 260 Responders (n=27) | 22 |
Evaluation of the mean changes in BASDAI in subjects with adalimumab exposure from Baseline through 5 years for the effect of adalimumab on structural damage. Partial remission was calculated as follows: A value below 20 on a 0 - 100-point scale in each of the four domains of the ASAS (Patient's Global Assessment of Disease Activity, Pain, Function and Inflammation). Partial remission is also regarded as a low disease activity state.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 23 |
| Week 24 Responders (n=80) | 25 |
| Week 52 Responders (n=78) | 31 |
| Week 76 Responders (n=75) | 33 |
| Week 104 Responders (n=74) | 35 |
| Week 128 Responders (n=70) | 31 |
| Week 156 Responders (n=69) | 28 |
| Week 180 Responders (n=62) | 29 |
| Week 208 Responders (n=67) | 32 |
| Week 220 Responders (n=64) | 29 |
| Week 232 Responders (n=62) | 34 |
| Week 244 Responders (n=54) | 25 |
| Week 260 Responders (n=27) | 16 |
BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. BASMI 0 = indicates mild disease involvement, 1 = moderate disease, and 2 = severe disease involvement. The results for cervical rotation and lumbar side flexion are the means of the left and right measurements. Scoring range 0-10. The higher the BASMI score, the more severe was the subject's limitation of movement due to their AS.
| cm | Adalimumab |
|---|---|
| Week 12 (n=82) | -0.42 ± 1.124 |
| Week 24 (n=80) | -0.50 ± 1.146 |
| Week 52 (n=78) | -0.61 ± 1.492 |
| Week 76 (n=75) | -0.64 ± 1.321 |
| Week 104 (n=74) | -0.78 ± 1.550 |
| Week 128 (n=69) | -1.01 ± 1.477 |
| Week (156 (n=69) | -1.00 ± 1.426 |
| Week 180 (n=62) | -1.03 ± 1.746 |
| Week 208 (n=67) | -1.04 ± 1.628 |
| Week 220 (n=64) | -0.86 ± 1.521 |
| Week 232 (n=60) | -0.88 ± 1.541 |
| Week 244 (n=51) | -1.00 ± 1.659 |
| Week 260 (n=27) | -0.70 ± 1.325 |
The EDASMI is a composite spinal mobility index comprised of 4 measures: 1) cervical rotation, 2) lumbar side flexion, 3) chest expansion, and 4) hip internal rotation spread. A grade of 0-4 scoring system was developed for each of the measures. The sum of 4 items (range 0 to 16) provide the EDASMI score. Decrease in EDASMI represents improvement. All EDASMI measures were done with a simple tape measure and recorded in centimeters (cm) by a rheumatologist and a clinician nurse.
| cm | Adalimumab |
|---|---|
| Week 12 (n=82) | -1.11 ± 1.990 |
| Week 24 (n=80) | -1.16 ± 2.143 |
| Week 52 (n=78) | -1.47 ± 2.408 |
| Week 104 (n=75) | -1.24 ± 2.357 |
| Week 128 (n=69) | -1.59 ± 3.124 |
| Week 156 (n=69) | -1.50 ± 3.457 |
| Week 180 (n=62) | -1.76 ± 3.227 |
| Week 208 (n=67) | -1.41 ± 3.705 |
| Week 220 (n=64) | -1.34 ± 3.301 |
| Week 232 (n=60) | -1.65 ± 3.267 |
| Week 244 (n=51) | -1.42 ± 3.199 |
| Week 260 (n=27) | -1.56 ± 3.566 |
The patient is in a sitting position on the examination table with the hands on the hips. A pen mark is made at the xiphisternum and a tape measure placed around the circumference of the patient's chest at this level. The patient is asked to take a deep breath and to exhale as completely as possible while looking directly ahead. The measurement (in cm) is noted. The patient is asked to inhale as deeply as possible and the measurement (in cm) is noted. The difference in the 2 measurement points (in cm) constitutes the value for CE. An increase in chest expansion represents improvement
| cm | Adalimumab |
|---|---|
| Week 12 (n=82) | 0.47 ± 1.907 |
| Week 24 (n=80) | 0.66 ± 1.717 |
| Week 52 (n=78) | 0.66 ± 1.803 |
| Week 104 (n=75) | 0.51 ± 1.875 |
| Week 128 (n=69) | 0.60 ± 2.287 |
| Week 156 (n=69) | 0.49 ± 1.881 |
| Week 180 (n=62) | 0.57 ± 1.960 |
| Week 208 (n=67) | 0.60 ± 2.252 |
| Week 220 (n=64) | 0.46 ± 2.013 |
| Week 232 (n=60) | 0.44 ± 2.082 |
| Week 244 (n=51) | 0.39 ± 2.074 |
| Week 260 (n=27) | 0.52 ± 2.112 |
MASES is measured by scoring of entheses of 0 (no tenderness) to 3 (severe tenderness) at 13 sites on the body. The score was derived as the sum of the 13 scores divided by 3 and the total range is 0 (no tenderness) to 13 (severe tenderness).
| Units on a scale | Adalimumab |
|---|---|
| Week 12 (n=82) | -2.26 ± 5.335 |
| Week 24 (n=80) | -3.26 ± 4.608 |
| Week 52 (n=77) | -3.61 ± 5.573 |
| Week 76 (n=59) | -3.56 ± 5.392 |
| Week 104 (n=74) | -3.66 ± 5.253 |
| Week 128 (n=52) | -3.52 ± 5.207 |
| Week 156 (n=67) | -3.27 ± 5.224 |
| Week 180 (n=50) | -3.72 ± 4.887 |
| Week 208 (n=66) | -4.11 ± 5.114 |
| Week 232 (n=48) | -3.81 ± 5.640 |
| Week 260 (n=49) | -5.47 ± 5.393 |
BAS-G consisted of two questions that asked the subject to indicate, on a 10 cm VAS, the effect the disease had on their well being over 1) last week, and 2) last 6 months. BAS-G was measured by two VAS scores (0 to 100 mm) to reflect the effect of Ankylosing Spondylitis on subject's well-being over the past week and over the last 6 months, respectively. The average of these two scores was reported. The mean of the two scores give a BAS-G score of 0-10.
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -23.41 ± 20.456 |
| Week 24 (n=80) | -32.78 ± 23.638 |
| Week 52 (n=78) | -39.40 ± 23.975 |
| Week 76 (n=75) | -42.63 ± 23.133 |
| Week 104 (n=74) | -44.78 ± 22.845 |
| Week 128 (n=70) | -43.28 ± 25.578 |
| Week 156 (n=69) | -44.30 ± 23.826 |
| Week 180 (n=62) | -45.05 ± 22.934 |
| Week 208 (n=67) | -45.08 ± 22.681 |
| Week 220 (n=64) | -46.73 ± 21.367 |
| Week 232 (n=62) | -45.56 ± 23.453 |
| Week 244 (n=54) | -53.69 ± 18.349 |
| Week 260 (n=27) | -50.93 ± 18.478 |
Change from Baseline in the swollen joint index. An assessment of 44 joints for SJC done by physical examination. Joint swelling was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).
| score on scale | Adalimumab |
|---|---|
| Week 12 (n=82) | -0.29 ± 4.171 |
| Week 24 (n=80) | -1.00 ± 4.792 |
| Week 52 (n=78) | -1.45 ± 4.497 |
| Week 76 (n=59) | -0.92 ± 4.427 |
| Week 104 (n=51) | -0.81 ± 5.789 |
| Week 128 (n=70) | -0.04 ± 2.592 |
| Week 156 (n=68) | -1.26 ± 5.231 |
| Week 180 (n=50) | -1.38 ± 4.453 |
| Week 208 (n=66) | -1.29 ± 5.737 |
| Week 232 (n=48) | -0.33 ± 2.300 |
| Week 260 (n=49) | -2.37 ± 5.619 |
Assessment of 46 joints for TJC was done by physical examination. Joint tenderness was classified as present ("1"), absent ("0") or injected/replaced ("9"). The joints assessed were: Sternoclavicular, Acromioclavicular, Shoulder, Elbow, Wrist, Metacarpophalangeal (1-5), Thumb interphalangeal, Proximal interphalangeal (2-5, Knee, Ankle, and Metatarsophalangeal (1-5).
| score on scale | Adalimumab |
|---|---|
| Week 12 (n=82) | -1.66 ± 6.639 |
| Week 24 (n=80) | -2.36 ± 6.582 |
| Week 52 (n=78) | -3.63 ± 5.920 |
| Week 76 (n=59) | -3.34 ± 7.184 |
| Week 104 (n=74) | -2.78 ± 7.731 |
| Week 128 (n=52) | -3.10 ± 6.307 |
| Week 156 (n=68) | -2.69 ± 8.086 |
| Week 180 (n=50) | -2.90 ± 7.833 |
| Week 208 (n=66) | -3.48 ± 7.341 |
| Week 232 (n=48) | -3.23 ± 7.197 |
| Week 260 (n=49) | -5.84 ± 7.290 |
The physician will globally assess the subject's current disease state using a VAS scale with 0 being very good and 100 being very bad.
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -24.80 ± 24.892 |
| Week 24 (n=80) | -33.46 ± 28.197 |
| Week 52 (n=78) | -38.68 ± 24.745 |
| Week 76 (n=75) | -38.21 ± 24.570 |
| Week 104 (n=74) | -41.96 ± 23.205 |
| Week 128 (n=70) | -42.26 ± 23.083 |
| Week 156 (n=69) | -38.75 ± 25.728 |
| Week 180 (n=62) | -42.84 ± 25.870 |
| Week 208 (n=66) | -41.27 ± 26.348 |
| Week 220 (n=63) | -43.92 ± 22.369 |
| Week 232 (n=58) | -43.60 ± 23.357 |
| Week 244 (n=50) | -52.98 ± 16.340 |
| Week 260 (n=27) | -50.33 ± 19.958 |
The subject was to assess his/her nocturnal pain intensity for the past week using a Nocturnal Pain Visual Analog Scale (Nocturnal Pain VAS). The range was 0 to 100 mm with no pain being indicated by 0 and worse possible pain by 100.
| mm | Adalimumab |
|---|---|
| Week 12 (n=82) | -25.49 ± 29.566 |
| Week 24 (n=80) | -28.08 ± 31.414 |
| Week 52 (n=78) | -33.88 ± 30.432 |
| Week 76 (n=75) | -34.87 ± 29.715 |
| Week 104 (n=74) | -37.07 ± 28.661 |
| Week 128 (n=70) | -36.77 ± 29.030 |
| Week 156 (n=69) | -34.91 ± 30.125 |
| Week 180 (n=62) | -33.50 ± 30.180 |
| Week 208 (n=67) | -34.00 ± 29.757 |
| Week 220 (n=64) | -35.33 ± 28.620 |
| Week 232 (n=62) | -34.11 ± 30.186 |
| Week 244 (n=54) | -40.61 ± 26.873 |
| Week 260 (n=27) | -33.41 ± 30.147 |
The FACIT-Fatigue scale: overall score of 13 general questions divided into four primary Quality of Life (QoL) domains: 1) Physical Well-Being, 2) Social/Family Well-Being, 3) Emotional Well-Being, and 4) Functional Well-Being. For each question subject rates his/her condition for the past week on a 5-point scale ranging from 0 (not at all) to 4 (very much). The score ranges from 0 (highest level of fatigue) to 52 with 52 being the lowest level of fatigue.
| unit on a scale | Adalimumab |
|---|---|
| Week 12 (n=74) | 9.49 ± 9.994 |
| Week 24 (n=53) | 9.03 ± 11.225 |
| Week 52 (n=78) | 11.48 ± 10.331 |
| Week 76 (n=59) | 11.61 ± 11.171 |
| Week 104 (n=74) | 12.46 ± 10.520 |
| Week 128 (n=52) | 11.08 ± 11.396 |
| Week 156 (n=68) | 11.62 ± 11.391 |
| Week 180 (n=50) | 10.56 ± 10.011 |
| Week 280 (n=66) | 11.60 ± 10.761 |
| Week 232 (n=48) | 10.13 ± 11.112 |
| Week 260 (n=49) | 16.17 ± 9.276 |
Change from Baseline in the SF-36 Health Survey Index completed by Subject to help subject keep track of how he/she was feeling and how well he/she was able to do usual activities. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicate improvement.
| score on scale | Adalimumab |
|---|---|
| Week 12 (n=74) | 7.60 ± 8.320 |
| Week 24 (n=53) | 9.26 ± 9.389 |
| Week 52 (n=78) | 10.63 ± 8.982 |
| Week 76 (n=59) | 11.26 ± 8.685 |
| Week 104 (n=74) | 11.29 ± 9.668 |
| Week 128 (n=50) | 11.76 ± 8.868 |
| Week 156 (n=68) | 11.73 ± 9.726 |
| Week 180 (n=48) | 10.74 ± 10.781 |
| Week 208 (n=60) | 12.42 ± 9.925 |
| Week 232 (n=21) | 10.88 ± 10.401 |
| Week 260 (n=5) | 12.19 ± 8.410 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0(no functioning)to 100 (highest level of functioning). Responders were subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=74) | 51 |
| Week 24 Responders (n=53) | 41 |
| Week 52 Responders (n=78) | 65 |
| Week 76 Responders (n=59) | 50 |
| Week 104 Responders (n=74) | 61 |
| Week 128 Responders (n=50) | 43 |
| Week 156 Responders (n=68) | 56 |
| Week 180 Responders (n=48) | 38 |
| Week 208 Responders (n=60) | 49 |
| Week 232 Responders (n=21) | 15 |
| Week 260 Responders (n=5) | 4 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Change from Baseline in the SF-36 Health Survey Index was completed by Subject. Components of the SF-36 included the PCS and MCS, respectively. An increase in SF-36 PCS or MCS indicated improvement.
| score on scale | Adalimumab |
|---|---|
| Week 12 (n=74) | 6.91 ± 9.109 |
| Week 24 (n=53) | 3.88 ± 10.617 |
| Week 52 (n=78) | 6.14 ± 10.466 |
| Week 76 (n=59) | 7.00 ± 9.469 |
| Week 104 (n=74) | 6.45 ± 10.821 |
| Week 128 (n=50) | 4.89 ± 11.234 |
| Week 156 (n=68) | 5.76 ± 10.687 |
| Week 180 (n=48) | 5.30 ± 11.434 |
| Week 208 (n=60) | 6.85 ± 10.366 |
| Week 232 (n=21) | 9.00 ± 11.213 |
| Week 260 (n=5) | 9.40 ± 13.224 |
SF-36 is a standardized survey completed by Subject, evaluating 8 aspects of functional health and well being; physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, and mental health. The score for a section is an average of the individual question scores, which are scaled 0 (no functioning) to 100 (highest level of functioning). Responders are subjects with MCID \> 3 points. Minimal clinically important difference (MCID) for PCS was determined by a \>= 3.0 point increase during exposure to adalimumab.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=74) | 49 |
| Week 24 Responders (n=53) | 29 |
| Week 52 Responders (n=78) | 50 |
| Week 76 Responders (n=59) | 39 |
| Week 104 Responders (n=74) | 46 |
| Week 128 Responders (n=50) | 30 |
| Week 156 Responders (n=68) | 42 |
| Week 180 Responders (n=48) | 27 |
| Week 208 Responders (n=60) | 41 |
| Week 232 Responders (n=21) | 16 |
| Week 260 Responders (n=5) | 4 |
Change from baseline in Health Utility Index Mark 3 (HUI-3) was reported. The HUI-3 is a generic approach to the measurement of health status and assessment of HRQL. The HUI-3 was comprised of two complementary components. The first component was a multi-attribute health status classification system that was used to describe health status. The second component was a multi-attribute utility function that was used to value health status as measured within the corresponding multi-attribute health status classification system. An increase in the HUI-3 score represents improvement.
| score on scale | Adalimumab |
|---|---|
| Week 24 (n=81) | 0.17 ± 0.234 |
| Week 52 (n=62) | 0.21 ± 0.223 |
| Week 104 (n=74) | 0.19 ± 0.245 |
| Week 128 (n=47) | 0.19 ± 0.271 |
| Week 156 (n=62) | 0.24 ± 0.254 |
| Week 180 (n=49) | 0.23 ± 0.259 |
| Week 208 (n=65) | 0.24 ± 0.257 |
| Week 232 (n=47) | 0.18 ± 0.306 |
| Week 260 (n=48) | 0.27 ± 0.249 |
ASQoL determined subject's quality of life and is comprised of 18 questions (yes or no) to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score or index. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement.
| score on a scale | Adalimumab |
|---|---|
| Week 12 (n=74) | -3.90 ± 4.556 |
| Week 24 (n=53) | -3.80 ± 4.993 |
| Week 52 (n=78) | -5.40 ± 4.724 |
| Week 76 (n=59) | -5.47 ± 4.830 |
| Week 104 (n=74) | -5.55 ± 4.593 |
| Week 128 (n=52) | -5.46 ± 4.741 |
| Week 156 (n=68) | -5.51 ± 5.015 |
| Week 180 (n=50) | -4.95 ± 5.415 |
| Week 208 (n=66) | -5.80 ± 5.127 |
| Week 232 (n=48) | -5.35 ± 5.538 |
| Week 160 (n=49) | -7.46 ± 4.811 |
ASQoL determined subject's quality of life comprised of 18 questions to be completed by the subject. Each statement on the ASQoL is given a score of "1" or "0." All item scores were summed to give a total score. Total scores ranged from 0 (good quality of life) to 18 (poor quality of life) related to ability to cope, relationships, mood, sleep, motivation, activities of everyday living, independence, and social life. Decrease in ASQoL score represents improvement. Responders are subjects with MCID \<= -1.8 points. MCID was determined by a \>= 1.8 score decrease during exposure to adalimumab.
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=74) | 48 |
| Week 24 Responders (n=53) | 27 |
| Week 52 Responders (n=78) | 60 |
| Week 76 Responders (n=59) | 42 |
| Week 104 Responders (n=74) | 59 |
| Week 128 Responders (n=52) | 41 |
| Week 156 Responders (n=68) | 50 |
| Week 180 Responders (n=50) | 37 |
| Week 208 Responders (n=66) | 51 |
| Week 232 Responders (n=48) | 36 |
| Week 260 Responders (n=49) | 43 |
Completed by subject at each visit. The MCIS was a patient reported outcome where the subjects were expected to respond (yes/no) to the following question: Considering all the different ways your disease is affecting you, if you would stay in this state for the next months, do you consider that your current state is satisfactory? An increase in PASS indicates improvement. During earlier weeks of the study PASS was measured/reported as minimal clinically important state (MCIS).
| participants | Adalimumab |
|---|---|
| Week 12 Responders (n=82) | 35 |
| Week 24 Responders (n=80) | 44 |
| Week 52 Responders (n=78) | 50 |
| Week 76 Responders (n=75) | 50 |
| Week 104 Responders (n=71) | 49 |
| Week 128 Responders (n=51) | 35 |
| Week 156 Responders (n=68) | 48 |
| Week 180 Responders (n=48) | 32 |
| Week 208 Responders (n=64) | 42 |
| Week 232 Responders (n=47) | 34 |
| Week 260 Responders (n=46) | 37 |
Cartilage and bone degradation were assessed by evaluating changes in MMP-3. A decrease in MMP-3 represents improvement.
| ng/mL | Adalimumab |
|---|---|
| Week 12 (n=73) | -29.06 ± 98.960 |
| Week 24 (n=52) | -6.31 ± 20.115 |
| Week 52 (n=78) | -24.89 ± 97.671 |
| Week 76 (n=60) | -24.64 ± 102.536 |
| Week 104 (n=74) | -23.05 ± 94.471 |
| Week 128 (n=51) | -7.37 ± 21.704 |
| Week 156 (n=66) | -33.71 ± 115.252 |
| Week 180 (n=50) | -12.56 ± 36.045 |
| Week 208 (n=62) | -31.37 ± 115.467 |
| Week 220 (n=26) | -67.52 ± 169.992 |
| Week 232 (n=36) | -9.88 ± 24.293 |
| Week 244 (n=27) | -67.88 ± 168.991 |
| Week 260 (n=27) | -11.60 ± 25.776 |
Cartilage and bone degradation were assessed by evaluating changes in CTX-II. A decrease in CTX-II represents improvement.
| ng/mmolcr | Adalimumab |
|---|---|
| Week 12 (n=74) | -72.27 ± 201.493 |
| Week 24 (n=52) | -39.87 ± 173.995 |
| Week 52 (n=75) | -51.56 ± 288.316 |
| Week 76 (n=58) | -89.93 ± 324.185 |
| Week 104 (n=73) | -65.04 ± 286.539 |
| Week 128 (n=51) | -96.53 ± 293.026 |
| Week 156 (n=64) | -125.92 ± 332.340 |
| Week 180 (n=45) | -168.02 ± 368.086 |
| Week 208 (n=55) | -172.18 ± 350.006 |
| Week 220 (n=26) | -175.42 ± 387.357 |
| Week 232 (n=35) | -113.54 ± 354.684 |
| Week 244 (n=26) | -150.15 ± 383.965 |
| Week 260 (n=24) | -141.42 ± 411.224 |
Cartilage degradation and bone resorption were assessed by evaluating changes in NTx. A decrease in NTx represents improvement.
| NM BCE | Adalimumab |
|---|---|
| Week 12 (n=73) | 0.63 ± 3.890 |
| Week 24 (n=53) | 0.33 ± 3.857 |
| Week 52 (n=78) | -1.02 ± 4.539 |
| Week 76 (n=60) | -0.05 ± 5.735 |
| Week 104 (n=74) | -0.17 ± 3.891 |
| Week 128 (n=50) | -1.00 ± 4.414 |
| Week 156 (n=66) | -0.82 ± 3.749 |
| Week 180 (n=50) | 0.52 ± 9.020 |
| Week 208 (n=62) | -1.94 ± 4.182 |
| Week 220 (n=26) | -3.10 ± 4.097 |
| Week 232 (n=36) | -1.47 ± 3.020 |
| Week 244 (n=27) | -4.59 ± 4.977 |
| Week 260 (n=27) | -2.89 ± 2.903 |
The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.
| score on a scale | Adalimumab | Placebo |
|---|---|---|
| Week 12 | -9.9 ± 1.01 | -0.8 ± 0.94 |
| Week 52 | -11.2 ± 1.08 | -13.7 ± 1.03 |
The S.P.A.R.C.C. MRI index is a tool for scoring inflammation and structural damage in both the spine and sacroiliac (SI) joints. The spinal SPARCC index score consists of 3 subscales (edema, intense edema, and deep edema). Edema was defined as the presence of increased STIR signal in each of 4 Discovertebral unit (DVU) quadrants and was assigned a score (0 = normal signal, 1 = increased signal). The scoring of edema was repeated for each of 3 consecutive sagittal slices with a maximum score of 12 per DVU (range for edema, 0-72). The total spinal SPARCC index score is 0 to 108.
| score on a scale | Adalimumab Exposure | Placebo |
|---|---|---|
| Week 12 | -4.1 ± 0.64 | -0.8 ± 0.60 |
| Week 52 | -5.4 ± 0.34 | -5.5 ± 0.32 |
Radiographic progression was based on change in mSASSS scoring (comparison of the means) from double-blind Baseline visit to Week 104. The mSASSS is the sum of the lumbar and cervical spine score ( 0 \[no change\] to 72 \[progression\]), derived from scoring the anterior site of the lumbar spine (T12 to S1) and the cervical spine (C2 to T1) as either 0 (normal), 1 (erosion, sclerosis, or squaring), 2 (syndesmophyte), 3 (bridging syndesmophyte), or N (vertebral body not evaluable). Data from NCT00195819 was compared with data from AS patients in OASIS.
| score on a scale | Any Adalimumab |
|---|---|
| Adalimumab in M03-606 (N=70) | 0.5 ± 0.36 |
| OASIS (N=169) | 0.9 ± 0.23 |
Collected over Adverse event data were collected through Week 260 of adalimumab exposure.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab | — | 20/82 (24.4%) | 78/82 (95.1%) |
| Event | Adalimumab |
|---|---|
| Diverticular perforationGastrointestinal disorders | 2/82 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/82 |
| DiplopiaEye disorders | 1/82 |
| PeritonitisGastrointestinal disorders | 1/82 |
| Umbilical herniaGastrointestinal disorders | 1/82 |
| AppendicitisInfections and infestations | 1/82 |
| Escherichia sepsisInfections and infestations | 1/82 |
| GastroenteritisInfections and infestations | 1/82 |
| PneumoniaInfections and infestations | 1/82 |
| PyelonephritisInfections and infestations | 1/82 |
| Event | Adalimumab |
|---|---|
| NasopharyngitisInfections and infestations | 38/82 |
| Upper Respiratory Tract InfectionInfections and infestations | 33/82 |
| Ankylosing SpondylitisMusculoskeletal and connective tissue disorders | 20/82 |
| HeadacheNervous system disorders | 20/82 |
| InfluenzaInfections and infestations | 14/82 |
| FatigueGeneral disorders | 13/82 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/82 |
| Back PainMusculoskeletal and connective tissue disorders | 11/82 |
| NauseaGastrointestinal disorders | 10/82 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 10/82 |
| Age Continuous(participants) | Adalimumab |
|---|---|
| <=40 years | 35 |
| Between 40 and 65 years | 45 |
| >=65 years | 2 |
| Age Continuous(years) | Adalimumab |
|---|---|
| Mean | 40.9 ± 10.97 |
| Sex: Female, Male(Participants) | Adalimumab |
|---|---|
| Female | 17 |
| Male | 65 |
| Region of Enrollment(participants) | Adalimumab |
|---|---|
| Canada | 82 |
The record gives a start of Dec 2003, a primary completion of Oct 2004 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 5 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab